Prof. Tadashi Watabe is an Associate Professor at the University of Osaka. He is a board-certified nuclear medicine physician with extensive expertise in theranostics and targeted alpha therapy. He serves as the PI of investigator-initiated clinical trials using 211At and PET research involving [18F]FAPI-74, [18F]FBPA, and [11C]HCA2969. He is also the Executive Congress Chair of the Theranostics World Congress 2027.
